Further strengthening the anti‐tumour activity of pyridostatin against PARPi‐resistant tumours is its inhibitory effect against BRCA1‐deleted PDTXs, which carry inactivating mutations in the REV7 (MAD2L2) gene (Bruna et al, 2016). The gene discussed is MAD2L2; the disease is neoplasm.